WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Yu Darvish extends scoreless innings streak to 25 in Padres' 9
Millions of donkeys killed each year to make medicine
Treaty referendum among issues raised with government at Waitangi
Homicide investigation launched after body found in Hastings
Justin Timberlake set to bring his The Forget Tomorrow World Tour to Australia in 2025
Christchurch man jailed for 14 years over role in US porn videos
Hong Kong denies entry to campaigner en route to Jimmy Lai trial — Radio Free Asia
In China, a factory is turning old wedding photographs into fuel
'The Apprentice,' about a young Donald Trump, premieres in Cannes
Government mulls expanding inquiry into Covid
NBA playoffs: Edwards leads Wolves to 98
Christchurch man jailed for 14 years over role in US porn videos